Pilot Trial of Leflunomide in Patients With CD30+ Lymphoproliferative Disorders
Latest Information Update: 08 Dec 2023
At a glance
- Drugs Leflunomide (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 26 Sep 2022 Planned primary completion date changed from 16 Jul 2022 to 16 Jul 2023.
- 07 Jun 2022 Planned primary completion date changed from 16 Jul 2023 to 16 Jul 2022.